Loreta Kondili, MD, PhD

Ntobeko Ntusi, BSc(Hons), MBChB, MD, DPhil

Serge Paul Eholié, MD, PhD

Management of toxicities from immunotherapy: an ESMO Clinical Practice Guideline - Caroline O'Leary, BA (Hons), MSc (LSE), MB BCh BAO (Hons), MRCPI

Pharmacological Optimization of Lung Cancer Treatment Webinar: Drug-Drug Interactions, Therapeutic Drug Monitoring, and Immunotherapy

Management of Toxicities from Immunotherapy: an ESMO Clinical Practice Guideline | Caroline O'Leary, BA (Hons), MSc (LSE), MB BCh BAO (Hons), MRCPI

Pharmacological Optimization of Lung Cancer Treatment Webinar: Drug-Drug Interactions, Therapeutic Drug Monitoring, and Immunotherapy

Therapeutic Drug Monitoring of Small Molecule Inhibitors in Patient with Lung Cancer: Ready for the Clinic?- Markus Jörger, MD, PhD, ClinPharm

Pharmacological Optimization of Lung Cancer Treatment Webinar: Drug-Drug Interactions, Therapeutic Drug Monitoring, and Immunotherapy

Therapeutic Drug Monitoring of Small Molecule Inhibitors in Patient with Lung Cancer: Ready for the Clinic? | Markus Jörger, MD, PhD, ClinPharm

Pharmacological Optimization of Lung Cancer Treatment Webinar: Drug-Drug Interactions, Therapeutic Drug Monitoring, and Immunotherapy

Drug-Drug Interactions between Small Molecule Inhibitors with Directly-Acting Oral Anti-coagulants (DOACs) in Patients with Lung Cancer. - Lorenz Van der Linden, PharmD, PhD

Pharmacological Optimization of Lung Cancer Treatment Webinar: Drug-Drug Interactions, Therapeutic Drug Monitoring, and Immunotherapy

Drug-Drug Interactions between Small Molecule Inhibitors with Directly-Acting Oral Anti-coagulants (DOACs) in Patients with Lung Cancer. | Lorenz Van der Linden, PharmD, PhD

Pharmacological Optimization of Lung Cancer Treatment Webinar: Drug-Drug Interactions, Therapeutic Drug Monitoring, and Immunotherapy

Anne Bhéreur, MD, CCFP (PC), FCFP